Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - What's Next?

Key Points

• Telix Pharmaceuticals shares jumped 5.4%, opening at $11.40 versus a prior close of $10.85 and last trading at $11.56.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $20.40; Wedbush and HC Wainwright set targets of $22 and $20, respectively.
• Several institutional investors increased or initiated positions in TLX, while the company continues developing targeted radiopharmaceuticals for cancer diagnosis and treatment.

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $10.85, but opened at $11.40. Telix Pharmaceuticals shares last traded at $11.56, with a volume of 86,235 shares traded.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on TLX. Citigroup restated a "buy" rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Wedbush reiterated an "outperform" rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Wednesday. Royal Bank Of Canada lowered Telix Pharmaceuticals from an "outperform" rating to a "sector perform" rating in a research note on Friday, July 17th. Finally, Weiss Ratings raised Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a report on Friday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $20.40.

Telix Pharmaceuticals Stock Up 5.4%

The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85. The company has a 50 day moving average price of $11.16 and a 200 day moving average price of $9.87.

Institutional Trading of Telix Pharmaceuticals

Several hedge funds have recently bought and sold shares of TLX. Rhumbline Advisers lifted its holdings in shares of Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company's stock valued at $25,000 after purchasing an additional 1,392 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company's stock worth $96,000 after buying an additional 8,423 shares in the last quarter. XTX Topco Ltd acquired a new stake in Telix Pharmaceuticals in the 4th quarter valued at approximately $89,000. XY Capital Ltd acquired a new stake in Telix Pharmaceuticals in the 1st quarter valued at approximately $120,000. Finally, IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals in the 2nd quarter valued at approximately $213,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source